ShareHub

The president said the U.S. “knew nothing” about the Israeli strike on Iran’s gas fields, which triggered Tehran's retaliatory attacks on Qatar's LNG facilit...

Forget AI Stocks: This Potentially Disruptive Biotech Could Soar By 181%, According to Wall Street | The Motley Fool

This stock could make you a fortune in the next two years, or lose you a whole lot of money.

AI is a valuable tool that could unlock significant value for these healthcare leaders and their shareholders.

Hims & Hers Stock Pops 40%: Everything You Need to Know | The Motley Fool

Hims & Hers shares are up over 40% on Monday after announcing a deal with Novo Nordisk.

The price of the company's popular GLP-1 drugs could come down by as much as 50% next year.

Hims & Hers stock traded more than 40% higher after the deal was announced.

Eli Lilly's stock is a bit expensive, even with a bit of a decline this year.

The company incurred a loss in its most recent quarterly results.

Investors were clearly impressed by the medical device specialist's fourth-quarter performance.

On March 9, 2026, a new Novo Nordisk pact reshaped this telehealth player’s GLP-1 strategy, margins, and legal risk profile.

A handful of the industry's income-generating gems are hiding in plain sight.

Evommune has two autoimmune disorder treatments with blockbuster potential.

Why BioNTech Stock Is Getting Crushed Today | The Motley Fool

Nothing about the recent past, present, or foreseeable future seems all that compelling.

2 Healthcare Stocks That Are Too Cheap to Ignore | The Motley Fool

These companies' shares have fallen too far, offering investors an attractive opportunity.

These biotechs are slowly making a name for themselves.

ResMed is a leader in CPAP machines and other medical devices that help millions breathe better.

Current shareholders were thrown an unexpected curveball that they actually should have been expecting.

They are down, but they are not out.

Is there any upside left for this rising biotech?

The biotech made a dramatic flip into profitability in its final quarter of 2025.

The company is pursuing a Phase 3 trial in its most exciting pipeline drug, and investors are awaiting potentially exciting data by the end of September.

It's important to always be prepared.

The multi-cancer early detection (MCED) company delivered some extremely bad news to investors in February, but the stock may attract risk tolerant investors...

These companies are highly unlikely to go under, no matter what happens.

Forget Oral Wegovy: This Weight Loss Drug Could Be an Even Bigger Winner | The Motley Fool

A new battle between these longtime rival companies will likely go the same way as their previous battles.

Intuitive Surgical Stock: Buy, Sell, or Hold? | The Motley Fool

Intuitive Surgical business momentum has been spectacular recently. But what should investors make of the valuation?

Regeneron's science and its Dupixent revenue are paving the way for it to further expand its portfolio.

Not many things have gone right for Novo Nordisk recently, but this is one of them.

They are relatively safe wealth compounders.

The drugmaker is getting its mojo back.

It won't be easy to knock the company off its pedestal.

It's off to a pretty decent start.

This stock continues to benefit from GLP-1 tailwinds -- and now it trades at a reasonable valuation.

A new product approval may be right around the corner.

The drama and uncertainty around Novo Nordisk and Hims & Hers Health might finally be ending.

Only the best dividend stocks can achieve "king" status.

This Promising GLP-1 Drug Could Give Novo Nordisk Investors Renewed Hope for the Stock | The Motley Fool

Novo Nordisk recently announced promising trial results for one of its GLP-1 drugs in development.

Why Eli Lilly Stock Just Dropped | The Motley Fool

Eli Lilly's stock price is based on growth rates that might fall short.